The study of GM1 [siagoside] ganglioside, a potential new Parkinson's disease medication

Trial Profile

The study of GM1 [siagoside] ganglioside, a potential new Parkinson's disease medication

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Dec 2015

At a glance

  • Drugs Siagoside (Primary)
  • Indications Parkinson's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 11 Aug 2009 Planned end date (1 May 2010) added as reported by ClinicalTrials.gov.
    • 13 Jun 2006 Status change in the treatment phase of the study. The parallel study examing the natural progression of Parkinson's disease is still open for recrutiment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top